Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441008 | 0.86 | LMNA (0.48) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL11631911 | 0.84 | CYP3A4 (0.46) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL12879049 | 0.84 | TRPV4 (0.50) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL25906691 | 0.82 | RXRA (0.50) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL16955601 | 0.82 | CYP3A4 (0.45) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL8286723 | 0.82 | ADRB2 (0.52) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL19368278 | 0.82 | CYP3A4 (0.45) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL11635848 | 0.82 | CYP3A4 (0.45) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL19414246 | 0.82 | UGT2B7 (0.45) | LMNAPTGS1TRPA1CACNA1CCYP3A4 | |
| SCHEMBL31171868 | 0.81 | CYP3A4 (0.48) | LMNAPTGS1TRPA1CACNA1CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | claimed |
| EP-4181943-B1 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | IPSEN BIOPHARM LTD (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-12403334-B2 | Low intensity ultrasound therapy | B G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2025-09-02 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | STANFORD RES INST INT (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-3863638-B1 | PHOSPHODIESTERASE INHIBITORS | UNIV NEBRASKA (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-0027952-B1 | PROCESS FOR PREPARING N,O-DISUBSTITUTED URETHANES | BAYER AG (DE) | 1983-04-13 | — | — | EP | disclosed |
| EP-0027953-B1 | PROCESS FOR PREPARING N,O-DISUBSTITUTED URETHANES | BAYER AG (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0028331-B1 | Process for preparing urethanes | BAYER AG (DE) | 1982-12-15 | — | — | EP | disclosed |
| EP-0063299-A1 | Process for the preparation of N-aryl-2,4-oxazolidine diones | BAYER AG (DE) | 1982-10-27 | — | — | EP | disclosed |
| EP-0059400-A2 | Process for the preparation of urethanes | BAYER AG (DE) | 1982-09-08 | — | — | EP | disclosed |
| EP-0027952-A1 | Process for preparing N,O-disubstituted urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| EP-0027940-A1 | Process for preparing urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| EP-0027953-A1 | Process for preparing N,O-disubstituted urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| US-4219570-A | Insect repellents and a method of repelling insects | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-08-26 | — | — | US | disclosed |
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | LMNA 2226/4885PTGS1 3690/4885TRPA1 4876/4885 |
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | RNASEH1, RNASEL, DNASE1 | LMNA 1328/4885PTGS1 2297/4885TRPA1 4601/4885 |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | LMNA 1927/4885PTGS1 1233/4885TRPA1 4031/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | LMNA 1876/4885PTGS1 3753/4885TRPA1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.